Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTOG 0525: Dose-Dense vs Standard Temozolomide in Glioblastoma
NCT00304031Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Jan 2006
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) and Gliosarcoma (GS) (3 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 4.4 years. Started Jan 2006; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00304031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304031.